NCT05158517View on ClinicalTrials.gov

VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)

Active, not recruitingOBSERVATIONAL
Enrollment

349

Participants

Timeline

Start Date

March 20, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 20, 2025

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Subcutaneous vedolizumab

Patients will be switched from IV vedolizumab into subcutaneous vedolizumab

Trial Locations (1)

38000

Thomas Chateau, Grenoble

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

OTHER

NCT05158517 - VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER) | Biotech Hunter | Biotech Hunter